{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:17:05Z","timestamp":1780085825243,"version":"3.54.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115178","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T17:28:08Z","timestamp":1698254888000},"page":"115178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis"],"prefix":"10.1016","volume":"168","author":[{"given":"Elias C.","family":"Padilha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengbi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Zawatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Christine V.","family":"Malicdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-4976","authenticated-orcid":false,"given":"George","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malliga R.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Gaucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-7253","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Ravenelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resat","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115178_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0193-2020","article-title":"Hermansky-Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease","volume":"30","author":"Yokoyama","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.biopha.2023.115178_bib2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/pcmr.12915","article-title":"Novel variants in the BLOC1S3 gene in patients presenting a mild form of Hermansky-Pudlak syndrome","volume":"34","author":"Pennamen","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.biopha.2023.115178_bib3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5482\/HAMO-14-06-0024","article-title":"Hermansky-Pudlak syndrome. Overview of clinical and molecular features and case report of a new HPS-1 variant","volume":"34","author":"Sanchez-Guiu","year":"2014","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.biopha.2023.115178_bib4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1056\/NEJM199804303381803","article-title":"Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome)","volume":"338","author":"Gahl","year":"1998","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115178_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1378\/chest.117.1.129","article-title":"Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1","volume":"117","author":"Brantly","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2023.115178_bib6","first-page":"333","article-title":"Albinism and Hermansky-Pudlak syndrome in Puerto Rico","volume":"82","author":"Witkop","year":"1990","journal-title":"Boletin De. la Asoc. Med. De. Puerto Rico"},{"key":"10.1016\/j.biopha.2023.115178_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.471","article-title":"CB1 R and iNOS are distinct players promoting pulmonary fibrosis in Hermansky-Pudlak syndrome","volume":"11","author":"Cinar","year":"2021","journal-title":"Clin. Transl. Med"},{"key":"10.1016\/j.biopha.2023.115178_bib8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db20-0078","article-title":"Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms","volume":"69","author":"Roger","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2023.115178_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87336","article-title":"Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis","volume":"1","author":"Cinar","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2023.115178_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92281","article-title":"Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis","volume":"2","author":"Cinar","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2023.115178_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bph.14849","article-title":"Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease","volume":"177","author":"Udi","year":"2020","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2023.115178_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.744857","article-title":"Peripheral Hybrid CB1R and iNOS antagonist MRI-1867 displays anti-fibrotic efficacy in bleomycin-induced skin fibrosis","volume":"12","author":"Zawatsky","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2023.115178_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","article-title":"The therapeutic potential of second and third generation CB1R antagonists","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.biopha.2023.115178_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40262-019-00741-9","article-title":"Physiologically based pharmacokinetic modelling for first-in-human predictions: an updated model building strategy illustrated with challenging industry case studies","volume":"58","author":"Miller","year":"2019","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115178_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249594","article-title":"Physiologically based metformin pharmacokinetics model of mice and scale-up to humans for the estimation of concentrations in various tissues","volume":"16","author":"Zake","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115178_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1208\/s12248-016-9956-4","article-title":"A physiologically based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children","volume":"18","author":"Lukacova","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2023.115178_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1208\/s12248-015-9836-3","article-title":"A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans","volume":"18","author":"Bi","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.biopha.2023.115178_bib19","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/j.bmc.2019.05.037","article-title":"Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity","volume":"27","author":"Sun","year":"2019","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.biopha.2023.115178_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bmc.2016.12.049","article-title":"Highly predictive and interpretable models for PAMPA permeability","volume":"25","author":"Sun","year":"2017","journal-title":"Bioorg. Med Chem."},{"key":"10.1016\/j.biopha.2023.115178_bib21","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2023.115178_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13321-020-00426-7","article-title":"Predicting liver cytosol stability of small molecules","volume":"12","author":"Shah","year":"2020","journal-title":"J. Chemin.-."},{"key":"10.1016\/j.biopha.2023.115178_bib23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1124\/dmd.108.020834","article-title":"Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data","volume":"36","author":"Kilford","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115178_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114102","article-title":"NOX2 inhibitor GSK2795039 metabolite identification towards drug optimization","volume":"201","author":"Padilha","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2023.115178_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1021\/js980236p","article-title":"General solution for diffusion\u2010controlled dissolution of spherical particles. 1. Theory","volume":"88","author":"Wang","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.115178_bib26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jps.22778","article-title":"Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility","volume":"101","author":"Johnson","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.115178_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/psp4.33","article-title":"Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK","volume":"4","author":"Wagner","year":"2015","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"10.1016\/j.biopha.2023.115178_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2023.115178_bib29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/00498250802050880","article-title":"Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions","volume":"38","author":"Elsby","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.biopha.2023.115178_bib30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.117.077040","article-title":"Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes\/microsomes and implications for experimental methodology","volume":"45","author":"Wood","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115178_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/dmd.118.085191","article-title":"Use of segregated hepatocyte scaling factors and cross-species relationships to resolve clearance dependence in the prediction of human hepatic clearance","volume":"47","author":"Hallifax","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115178_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/dmd.118.081315","article-title":"Y.-a. Bi, M. Niosi, S. Modi, A.D. Rodrigues, L.M. Tremaine, and M.V. Varma, Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro\u2013in vivo scaling of hepatic uptake clearance","volume":"46","author":"De Bruyn","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115178_bib33","first-page":"1316","article-title":"Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans","volume":"29","author":"Naritomi","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2023.115178_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00204-019-02397-7","article-title":"Use of an in vitro-in silico testing strategy to predict inter-species and inter-ethnic human differences in liver toxicity of the pyrrolizidine alkaloids lasiocarpine and riddelliine","volume":"93","author":"Ning","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2023.115178_bib35","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s40262-018-0631-z","volume":"57","author":"Song","year":"2018","journal-title":"Clin. Pharm."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:11:20Z","timestamp":1779916280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223009691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"alternative-id":["S0753332223009691"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115178","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115178"}}